Effects of luseogliflozin on intravaginal bacteria and fungi in patients with type 2 diabetes

Effects of luseogliflozin on intravaginal bacteria and fungi in patients with type 2 diabetes - Effects of luseogliflozin on intravaginal bacteria and fungi

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000025334

Enrollment

Registered

2016-12-20

Start date

2014-11-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

None listed

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Type 2 diabetes patients. Obtained written informed consent from the patients before participation.

Exclusion criteria

Exclusion criteria: Having severe nephropathy.

Design outcomes

Primary

Measure	Time frame
Intravaginal fungi and Gram-positive and -negative bacilli	—

Secondary

Measure	Time frame
Body mass index, HbA1c, and serum triglyceride and total, HDL, and LDL cholesterol levels	—

Countries

Japan

Contacts

Public ContactMasataka Kusunoki

Nagoya University Research Center of Health, Physical Fitness and Sports

info@tonyo.jp052-789-3946

Outcome results